More on LGND
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $290.07 |
|
|||
| Open | $290.07 | ||||
| 52 Wk High | $139.79 | ||||
| 52 Wk Low | $82.07 | ||||
| Day High | $290.07 | ||||
| Day Low | $290.07 | ||||
| P/E | 674.58 | ||||
| EPS | $0.43 | ||||
| Volume | 1,372 | ||||
- Form 8-K LIGAND PHARMACEUTICALS For: Sep 22
- Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea
- Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
- Form 4 LIGAND PHARMACEUTICALS For: Sep 10 Filed by: Zimmermann Martine
- Form 144 LIGAND PHARMACEUTICALS Filed by: Zimmermann Martine
- Ligand to Participate in September Investor Conferences
- Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Espinoza Octavio
- Form 4 LIGAND PHARMACEUTICALS For: Aug 12 Filed by: Haas Jason
- Leerink Starts Ligand Pharma (LGND) at Outperform
- Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
Entities mentioned with LGND
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Roth Capital | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
